ClinicalTrials.gg
Not yet recruitingNCT07937423DYNAMICUpdated Nov 16, 2026

DYNAMIC Pilot Optimization Trial

An interventional study of Relaxation Training (RT) and Cognitive Behavioral Therapy Skills Training (CBT) in Advanced Cancer, Metastatic Cancer and Cancer Survivorship, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Not yet recruiting at 2 sites in United States. Open to participants aged 25 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
25 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Neoplasm Metastasis by H. Lee Moffitt Cancer Center and Research Institute — 1 open to participants now, 2 under way, none of them phase 3. Neoplasm Metastasis · H. Lee Moffitt Cancer Center and Research Institute.

Planned enrollment
Largest of 33
56 · median 16
Started
2027
the only one that year
No phase
2 of 34
1 open now
Registered
34th of 34
by date

Among the 34 studies in Neoplasm Metastasis by H. Lee Moffitt Cancer Center and Research Institute, this one has the largest planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2027, is one of 2 with no phase, and was the 34th registered.

Neoplasm Metastasis

4,045 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 34 studies in Neoplasm Metastasis by H. Lee Moffitt Cancer Center and Research Institute is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 25 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Neoplasm Metastasis by H. Lee Moffitt Cancer Center and Research Institute, or all of them as a file.
02

Study summary

The purpose of this pilot optimization trial is to evaluate the feasibility and acceptability of using an optimization approach to refine DYNAMIC, a behavioral intervention designed to improve psychosocial well-being among young adults ages 25-39 with advanced cancer. This study is guided by the Multiphase Optimization Strategy (MOST) framework. Participants will be randomized using a 2x2x2 factorial design to receive up to three DYNAMIC intervention components: relaxation training (yes/no), cognitive behavioral therapy-based skills training (yes/no), and young-adult relevant health education (yes/no).

Read the detailed description

Young adults (YAs; ages 25-39) with advanced cancer face substantial psychosocial challenges related to navigating cancer and survivorship during a critical developmental life stage. Despite significant unmet psychosocial support needs, no behavioral interventions have been developed specifically for YAs with advanced cancer. To address this need, our team developed DYNAMIC, a multi-component and evidence-based behavioral intervention designed to improve psychosocial well-being among YAs with advanced cancer. DYNAMIC is delivered to YAs in a group format over videoconference and includes three candidate intervention components: relaxation training (RT), cognitive behavioral therapy-based skills training (CBT), and YA-relevant health education (HE). The goal of this pilot optimization trial is to evaluate the feasibility and acceptability of using an optimization approach to refine DYNAMIC, guided by the Multiphase Optimization Strategy (MOST) framework. In this preparation-phase pilot optimization trial, 56 YAs with advanced cancer will be randomized in groups using a balanced 2x2x2 factorial design. Groups of participants will be assigned to receive or not receive each of three intervention components: RT (yes/no), CBT (yes/no), and HE (yes/no), resulting in eight experimental conditions representing all possible combinations of the candidate intervention components. The primary outcomes are feasibility and acceptability (rates of recruitment, retention, attendance, satisfaction).

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer
  • Cancer Survivorship

Keywords

  • Young Adults
  • Advanced Cancer
  • Metastatic Cancer
  • Cancer Survivorship
  • Behavioral Intervention
  • Psychosocial Well-Being
  • Cognitive Behavioral Therapy
  • Relaxation Training
  • Health Education
  • eHealth
  • Telehealth
  • Multiphase Optimization Strategy
  • MOST
  • Optimization Trial
  • Factorial Design
  • Supportive Care Oncology
04

Who can participate

Ages eligible
25 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 25 to 39 years.
  • Diagnosed with or progressed to stage III or IV advanced cancer between ages 25 and 39.
  • Able to speak and read English.
  • of at least 6 months.
  • Able to provide .
  • Willing to be randomized to a study condition.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed or observed psychiatric or neurologic disorder that could interfere with participation (e.g., active psychosis).
  • Inability to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    RT + CBT + HE

    Behavioral: Relaxation Training (RT) · Behavioral: Cognitive Behavioral Therapy Skills Training (CBT) · Behavioral: Young Adult-Relevant Health Education (HE)

  • Experimental
    RT + CBT

    Behavioral: Relaxation Training (RT) · Behavioral: Cognitive Behavioral Therapy Skills Training (CBT)

  • Experimental
    RT + HE

    Behavioral: Relaxation Training (RT) · Behavioral: Young Adult-Relevant Health Education (HE)

  • Experimental
    RT

    Behavioral: Relaxation Training (RT)

  • Experimental
    CBT + HE

    Behavioral: Cognitive Behavioral Therapy Skills Training (CBT) · Behavioral: Young Adult-Relevant Health Education (HE)

  • Experimental
    CBT

    Behavioral: Cognitive Behavioral Therapy Skills Training (CBT)

  • Experimental
    HE

    Behavioral: Young Adult-Relevant Health Education (HE)

  • No intervention
    No Intervention

Interventions

  • BehavioralRelaxation Training (RT)

    A relaxation skills program.

  • BehavioralCognitive Behavioral Therapy Skills Training (CBT)

    A cognitive behavioral skills training program.

  • BehavioralYoung Adult-Relevant Health Education (HE)

    A health education program.

06

What researchers measure

Primary outcomes

  1. Feasibility: Recruitment

    The proportion of eligible young adults (ages 25-39) with advanced cancer who enroll in the study among all eligible individuals approached for participation.

    Time frame: Baseline

  2. Feasibility: Retention

    The proportion of enrolled participants who complete the final follow-up assessment.

    Time frame: 6 months

  3. Feasibility: Attendance at the group sessions

    The mean number of intervention sessions attended among participants assigned to experimental conditions.

    Time frame: 10 weeks

  4. Feasibility: Completion of study assessments

    The percentage of scheduled assessments completed, including baseline, post-intervention, and follow-up assessments.

    Time frame: 6 Months

  5. Acceptability: Satisfaction with weekly sessions

    The mean satisfaction score of individual intervention sessions assessed weekly among participants assigned to experimental conditions using a study-developed satisfaction survey. Responses are scored on a 0-4 Likert scale, with higher scores indicating greater satisfaction.

    Time frame: 10 weeks

  6. Acceptability: Satisfaction with overall program

    The mean satisfaction score of the overall intervention assessed at post-intervention using a study-developed satisfaction survey. Responses are scored on a 0-4 Likert scale, with higher scores indicating greater satisfaction.

    Time frame: Post-intervention, 3 months

07

Study locations

2 sites
  • The University of Arizona Department of Psychology
    Tucson, Arizona 85721, United States
    • Rina Fox, PhD · Principal investigator
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    • Laura Oswald, PhD · Principal investigator
    • Carley Geiss, PhD · Sub investigator
    • Leidy Isenalumhe, MD · Sub investigator
    • Vivien Yin, PhD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 291 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 19 months is below that.

Counting every sponsor, half of 316 studies reached it within 54 months; a quarter within 28 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Jan 2027
Primary completionEst.
Aug 2028
CompletionEst.
Apr 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937423
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Crystal Bryant
Contact
Crystal.Bryant@moffitt.org
813-745-2168
Yvelise Rodriguez
Contact
Yvelise.Rodriguez@moffitt.org
813-745-1814
Laura Oswald, PhD
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion